Using private demand studies to calculate socially optimal vaccine subsidies in developing countries

Journal of Policy Analysis and Management

Volumn 28, Issue 1, 2009, Pages 6-28

  Cook, Joseph ^a   Jeuland, Marc ^b   Maskery, Brian ^b   Lauria, Donald ^b   Sur, Dipika ^c   Clemens, John ^d   Whittington, Dale ^b,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b IL   (United States)

^c NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^d International Vaccine Institute   (South Korea)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE;

ARTICLE; CHOLERA; COST BENEFIT ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; ECONOMICS; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; IMMUNOLOGY; INDIA; PREVENTIVE HEALTH SERVICE; SOCIOLOGY; STATISTICAL MODEL; VACCINATION;

CHOLERA; CHOLERA VACCINES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; DISEASE TRANSMISSION, INFECTIOUS; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNIZATION PROGRAMS; INDIA; MODELS, ECONOMIC; SOCIOLOGY; VACCINATION;

EID: 58149340578     PISSN: 02768739     EISSN: 15206688     Source Type: Journal    
DOI: 10.1002/pam.20401     Document Type: Article

References (66)

1. Ahituv, A., Hotz, V. J., & Philipson, T. (1993). Will the AIDS epidemic be self-limiting? Evidence on the responsiveness of the demand for condoms to the prevalence of AIDS. Unpublished manuscript.
2. Ahituv, A., Hotz, V. J., & Philipson, T. (1996). The responsiveness of the demand for condoms to the local prevalence of AIDS. Journal of Human Resources, 31, 869-897.
3. Ali, M., Emch, M., Seidlein, L. v., Yunus, M., Sack, D. A., Rao, M., et al. (2005). Herd immunity conferred by killed oral cholera vaccines in Bangladesh: A reanalysis. The Lancet, 366, 44-49.
4. Anderson, R. M., & May, R. M. (1991). Infectious diseases of humans. Oxford, UK: Oxford University Press.
5. Barrett, S. (2004). Eradication versus control: The economics of global infectious disease policies. Bulletin of the World Health Organization, 82, 683-688.
6. Barrett, S., & Hoel, M. (2003). Optimal disease eradication. Unpublished manuscript, Oslo, Norway.
7. Becker, N., & Starczak, D. (1997). Optimal vaccination strategies for a community of house-holds. Mathematical Biosciences, 139, 117-132.
8. Beutels, P., Edmunds, W J., Antonanzas, F., Wit, G. A. D., Evans, D., Feilden, R., et al. (2002). Economic evaluation of vaccination programmes: A consensus statement focusing on viral hepatitis. Pharmacoeconomics, 20, 1-7.
9. Bhattacharya, S., Alberini, A., & Cropper, M. (2007). The value of mortality risk reductions in Delhi, India. Journal of Risk and Uncertainty, 34, 21-47.
10. Bloom, D. E., Canning, D., & Weston, M. (2005). The value of vaccination. World Economics, 6, 15-39.
11. Boulier, B. L., Datta, T. S., & Goldfarb, R. S. (2007). Vaccination externalities. The B. E. Journal of Economic Analysis and Policy, 7, Article 23.
12. Brito, D. L., Sheshinksi, E., & Intriligator, M. D. (1992). Externalities and compulsory vaccinations. Journal of Public Economics, 45, 69-90.
13. Canh, D. G., Whittington, D., Thoa, L. T. K., Utomo, N., Hoa, N. T., Poulos, C., et al. (2006). Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy and Planning, 21, 241-255.
14. Cook, J., Whittington, D., Canh, D. G., Johnson, F. R., & Nyamete, A. (2007). The reliability of stated preferences for cholera and typhoid vaccines with time to think in Hue, Vietnam. Economic Inquiry, 45, 100-114.
15. Cook, J., Jeuland, M., Maskery, B., Lauria, D., Sur, D., Clemens, J., & Whittington, D. (2008). Supplemental information for: Using private demand studies to calculate socially-optimal vaccine subsidies in developing countries. Evans School of Public Affairs Working Paper 2008-02, http://evans.washington.edu/research/working-papers/2008.
16. Cropper, M. L., Haile, M., Lampietti, J., Poulos, C., & Whittington, D. (2004). The demand for a malaria vaccine: Evidence from Ethiopia. Journal of Development Economics, 75, 303-318.
17. Deen, J., Seidlein, L. v., Sur, D., Agtini, M., Lucas, M. E. S., Lopez, A. L., et al. (2008). The high burden of cholera in children: Comparison of incidence from endemic areas in Asia and Africa. PLoS Neglected Tropical Diseases, 2, e173.
18. DeRoeck, D. (2008). Personal communication, March 2008.
19. Edmunds, W J., Brisson, M., Melegaro, A., & Gay, N. J. (2002). The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine, 20, 1316-1330.
20. Fine, P. E. M. (1993). Herd immunity: History, theory and practice. Epidemiologic Reviews, 15, 265-302.
21. Francis, P. J. (1997). Dynamic epidemiology and the market for vaccinations. Journal of Public Economics, 63, 383-406.
22. Galvani, A. P., Reluga, T. C., & Chapman, G. B. (2007). Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proceedings of the National Academy of Sciences (PNAS), 104, 5692-5697.
23. Geoffard, P.-Y., & Philipson, T. (1996). Rational epidemics and their public control. International Economic Review, 37, 603-624.
24. Gersovitz, M. (2003). Births, recoveries, vaccinations and externalities. In R. Arnott, B. Greenwald, R. Kanbur, & B. Nalebuff (Eds.), Economics for an imperfect world: Essays in honor of Joseph E. Stiglitz (pp. 469-483). Cambridge, MA: MIT Press.
25. Global Alliance for Vaccines and Immunization (GAVI). (2004). Guidelines for preparing proposals for GAVI/Vaccine Fund Investment: GAVI (Global Alliance for Vaccines & Immunization).
26. Grossman, M. (1972). On the concept of health capital and the demand for health. Journal of Political Economy, 223-255.
27. Hemenway, D. (1994). Economics of childhood immunization. Economic Inquiry, 32, 519-523.
28. Islam, Z., Maskery, B., Nyamete, A., Horowitz, M., Yunus, M., & Whittington, D. (2008). Private demand for cholera vaccines in rural Matlab, Bangladesh. Health Policy, 85, 184-195.
29. Jeuland, M., Clemens, J., Cook, J., Whittington, D., & Group, D. C. E. S. (2008). Cost effectiveness of new-generation oral cholera vaccines: A multi-country analysis. Submitted manuscript.
30. Jeuland, M., Lucas, M., Deen, J., Lazaro, N., & Whittington, D. (2008). Estimating the private benefits of vaccination against cholera in Beira, Mozambique: A travel cost application. Submitted manuscript.
31. Kim, D., Canh, D. G., Poulos, C., Thoa, L. T. K., Cook, J., Hoa, N. T., et al. (2008). Private demand for cholera vaccines in Hue, Vietnam. Value in Health, 11, 119-128.
32. Kremer, M. (1996). Integrating behavioral choice into epidemiological models of AIDS. The Quarterly Journal of Economics, 111, 549-573.
33. Lagarde, M., Haines, A., & Palmer, N. (2007). Conditional cash transfers for improving uptake of health interventions in low- and middle-income countries: A systematic review. Journal of the American Medical Association, 298, 1900-1910.
34. Lauria, D., & Stewart, J. (2007). Vaccination costs: Working paper, UNC Environmental Science & Engineering.
35. Laxminarayan, R., Mills, A. J., Breman, J. G., Measham, A. R., Alleyne, G., Claeson, M., et al. (2006). Advancement of global health: Key messages from the Diseases Control Priorities Project. Lancet, 367, 1193-1208.
36. Lee, G. M., Murphy, T. V., Lett, S., Cortese, M. M., Kretsinger, K., Schauer, S., et al. (2007). Cost effectiveness of pertussis vaccination in adults. American Journal of Preventive Medicine, 32, 186-193.
37. Li, Y.-C., Norton, E. C., & Dow, W. H. (2004). Influenza and pneumococcal vaccination demand responses to changes in infectious disease mortality. Health Services Research, 39, 905-926.
38. Lloyd, A., Patel, N., Scott, D. A., Runge, C., Claes, C., & Rose, M. (2008). Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: Considering a highrisk population and herd immunity effects. The European Journal of Health Economics, 9, 7-15.
39. Longini, I., Nizam, A., Ali, M., Yunus, M., Shenvi, N., & Clemens, J. D. (2007). Controlling endemic cholera with oral vaccines. PLoS Medicine, 4, 1776-1783.
40. Longini, I. M., Jr., Ackerman, E., & Elveback, L. R. (1978). An optimization model for influenza A epidemics. Mathematical Biosciences, 38, 141-157.
41. Lopez, A. L. (2007). Paving the way for control of cholera and typhoid fever in Kolkata, India: A project report of the NTCED-IVI collaboration 2002-2006.
42. Lucas, M., Jeuland, M., Deen, J., Lazaro, N., MacMahon, M., Nyamete, A., et al. (2007). Private demand for cholera vaccines in Beira, Mozambique. Vaccine, 25, 2599-2609.
43. Maskery, B., Islam, Z., Deen, J., & Whittington, D. (2008). An estimate of the economic value parents in rural Bangladesh place on ex ante risk reductions for their children, 16th Annual Conference of the European Association of Environmental and Resource Economists, Gothenburg, Sweden.
44. Miguel, E., & Kremer, M. (2004). Worms: Indentifying impacts on education and health in the presence of treatment externalities. Econometrica, 72, 159-217.
45. Mullahy, J. (1999). It'll only hurt a second? Microeconomic determinants of who gets flu shots. Health Economics, 8, 9-24.
46. Murray, J., McFarland, D. A., & Waldman, R. J. (1998). Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bulletin of the World Health Organization, 76, 343-352.
47. Naficy, A., Rao, M., Paquet, C., Antona, D., Sorkin, A., & Clemens, J. D. (1998). Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings. Journal of the American Medical Association, 279, 521-525.
48. Patel, R., Longini, I. M., & Halloran, M. E. (2005). Finding optimal vaccination strategies for pandemic influenza using genetic algorithms. Journal of Theoretical Biology, 234, 201-212.
49. Philipson, T. (1996). Private vaccination and public health: An empirical examination for U.S. measles. The Journal of Human Resources, 31, 611-630.
50. Philipson, T. (2000). Economic epidemiology and infectious disease. In A. J. Culyer & J. P Newhouse (Eds.), Handbook of health economics (pp. 1761-1799). Amsterdam: Elsevier.
51. Pigou, A. C. (1920). The economics of welfare. London: McMillan and Co.
52. Poulos, C., Riewpaiboon, A., Stewart, J. F., Nyamete, A., Guh, S., Clemens, J., et al. (2008). Costs of .illness due to endemic cholera in four sites in Asia. Unpublished manuscript, March, 2008.
53. Reichert, T. A., Sugaya, N., Fedson, D. S., Glezen, W. P., Simonsen, L., & Tashiro, M. (2001). The Japanese experience with vaccinating schoolchildren against influenza. The New England Journal of Medicine, 344, 889-896.
54. Schaecter, M., Engleberg, N. C., Eisenstein, B. I., & Medoff, G. (1998). Mechanisms of microbial disease (3rd ed.). Baltimore, Maryland: Williams and Wilkins.
55. Shanmugam, K. R. (2001). Self selection bias in the estimates of compensating differentials for job risks in India. The Journal of Risk and Uncertainty, 22, 263-275.
56. Simon, N. B., Cropper, M. L., Alberini, A., & Arora, S. (1999). Valuing mortality risk reductions in India: A study of compensating wage differentials. Washington, DC: The World Bank.
57. Sur, D., Cook, J., Chatterjee, S., Deen, J., & Whittington, D. (2006). Increasing the transparency of stated choice studies for policy analysis: Designing experiments to produce raw response graphs. Journal of Policy Analysis and Management, 26, 189-199.
58. Sur, D., Deen, J. L., Manna, B., Niyogi, S. K., Deb, A. K., Kanungo, S., et al. (2005). The burden of cholera in the slums of Kolkata, India: Data from a prospective, community-based study. Archives of Disease in Childhood, 90, 1175-1181.
59. Suraratdecha, C., Ainsworth, M., Tangcharoensathien, V., & Whittington, D. (2005). The private demand for an AIDS vaccine in Thailand. Health Policy, 71, 271-287.
60. Thiem, V D., Jacqueline L. Deen, Lorenz von Seidlein, Do Gia Canh, Dang Due Anh, JinKyung Park, Mohammad Ali, M.. Carolina Danovaro-Holliday, Nguyen Dinh Son, Nguyen Thai Hoa, Jan Holmgren, & John D. Clemens. (2006). Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine, 24, 4297-4303.
61. Todar, K. (2006). Online Textbook of Bacteriology. Online at www.textbookofbacteriology.net.
62. Venkatachalam, L. (2004). The contingent valuation method: A review. Environmental Impact Assessment Review, 24, 89-124.
63. Weite, R., Dobbelsteen, G. v. d., Bos, J. M., deMelker, H., Alphen, L. v., Spanjaard, L., et al. (2004). Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine, 23, 470-479.
64. Whittington, D., Pinheiro, A. C., & Cropper, M. (2003). The economic benefits of malaria prevention: a contingent valuation study in Marracuene, Mozambique. Journal of Health and Population in Developing Countries, 1-27.
65. Whittington, D., Sur, D., Cook, J., Chatterjee, S., Maskery, B., Lahiri, M., et al. (2008). Rethinking cholera and typhoid vaccination policies for the poor: Private demand in Kolkata, India. World Development, forthcoming.
66. World Health Organization (WHO). (2006). Cholera 2005. Weekly epidemiological record, 81, 297-308.